Cited by 24Amyotrophic Lateral Sclerosis ResearchSirtuins and Resveratrol in MedicineGenetic Neurodegenerative Diseases

Could sirtuin activities modify ALS onset and progression?

Open access
Tang, Bor Luen·2017·Cellular and Molecular Neurobiology

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with a complex etiology. Sirtuins have been implicated as disease-modifying factors in several neurological disorders, and in the past decade, attempts have been made to check if manipulating Sirtuin activities and levels could confer benefit in terms of neuroprotection and survival in ALS models. The efforts have largely focused on mutant SOD1, and while limited in scope, the results were largely positive. Here, the body of work linking Sirtuins with ALS is reviewed, with discussions on how Sirtuins and their activities may impact on the major etiological mechanisms of ALS. Moving forward, it is important that the potentially beneficial effect of Sirtuins in ALS disease onset and progression are assessed in ALS models with TDP-43, FUS, and C9orf72 mutations.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10571-016-0452-2

Cites

201 of 201 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • SIRT1 activators, including resveratrol, slow disease progression in ALS animal models.

    “treatment with SIRT1 activators, including resveratrol, ameliorates the disease progress in ALS animal models”

    From NAD+ in Brain Aging and Neurodegenerative Disorders (2019) · cites this paper as Tang, 2017

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

2 retracted

Flagged first, then by citations

Research works printed but not linked: 1

  1. Fecto F, Yan J, Vemula SP, Liu E, Yang Y, Chen W, Zheng JG, Shi Y, Siddique N, Arrat H, Donkervoort S, Ajroud-Driss S, Sufit RL, Heller SL, Deng HX, Siddique T (2011) SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch Neurol 68:1440–1446 [DOI] [PubMed] [Google Scholar]

Cited by

Sorted by citations

Authors
Tang, B. L.
Affiliations
National University of Singapore (SG)
Corresponding author
Tang, Bor Luen
Venue
Cellular and Molecular Neurobiology
Published
2016-12-10
Volume
37
Issue
7
Pages
1147-1160
ISSN
  • 0272-4340 (ISSN-L)
  • 1573-6830
OpenAlex
W2560651871
Cited by
24
References
201
Citations by year
2026: 1 · 2025: 2 · 2024: 4 · 2022: 3 · 2021: 2 · 2020: 5 · 2019: 2 · 2018: 1 · 2017: 4
FWCI
0.32
Type
journal article
Language
en
Open access
Locations
  • Cellular and Molecular Neurobiology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National University of Singapore (C-183-000-102-091)
Topics
  • Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
  • Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
Keywords
amyotrophic lateral sclerosis, sirtuins, disease-modifying therapy, neuroprotection, SOD1 mutations, TDP-43, FUS, C9orf72
MeSH terms
Superoxide Dismutase-1, Amyotrophic Lateral Sclerosis, Animals, Humans, Motor Neurons, Disease Progression, Sirtuins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review